SecBot SecBot
PRESS-RELEASE ·Filed Mar 12, 2026

LYEL

Lyell Immunopharma, Inc
MIXED
Impact 6/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The narrowing losses and extended cash runway into Q2 2027 reduce near-term dilution risk. Upcoming catalysts include mid-2027 pivotal data from PiNACLE trial supporting a potential BLA filing. Monitor progress in PiNACLE-H2H and LYL273 dose escalation for further de-risking.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$21.25
T+0 close · Mar 12, 2026 · via day close
Latest settled
−42.07%
T+60 · $12.31
Vs SPY
−53.69%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 13 $21.25entry
  2. T+1 · 8mo ago −0.56%α −1.59% · $21.13
  3. T+5 · 8mo ago −10.02%α −7.91% · $19.12
  4. T+20 · 7mo ago +16.71%α +13.12% · $24.80
  5. T+60 · 5mo ago −42.07%α −53.69% · $12.31
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lyell Immunopharma reported its Q4 and full-year 2025 financial results, highlighted by reduced net losses compared to the prior year, ongoing pivotal trials for ronde-cel in lymphoma, clinical progress with LYL273 in colorectal cancer, and a $50 million equity tranche closing. The company has $247.2 million in cash as of year-end 2025, with runway into Q2 2027.

Key Financial Metrics

Revenue
$36.0M
-41.0% YoY
Adj. EPS
$-0.61
GAAP: $-1.15
Deal Value
$50.0M

Key Facts

  • Net loss narrowed to $140.7M in Q4 2025 from $191.9M in Q4 2024; full-year loss decreased to $274.4M from $343.0M in 2024.
  • Cash, cash equivalents, and marketable securities were $247.2M as of December 31, 2025, excluding $50M raised in March 2026.
  • Patient dosing has commenced in the Phase 3 head-to-head PiNACLE-H2H trial of ronde-cel vs. axi-cel or liso-cel in 2L large B-cell lymphoma.
  • Seven new patients treated with LYL273 in mCRC since acquisition, with no dose-limiting toxicity and escalation to Dose Level 3.
  • Ronde-cel showed 93% best overall response rate and 76% complete response rate in 29 efficacy-evaluable patients in the 3L+ setting.
  • Second $50M tranche of $100M private placement closed in March 2026 after clinical milestone achievement.
  • Smital Shah appointed Chief Financial and Business Officer in March 2026.

Financial Impact

Reduced operating expenses and improved cash efficiency: non-GAAP net loss decreased to $33.1M (Q4) and $144.8M (full-year) from $45.9M and $159.5M in 2024. R&D spend decreased on a non-GAAP basis despite LYL273 acquisition costs.

net_losscash_runwayR&D_expenseG&A_expense

Risk Factors

  • High cash burn relative to market cap; future equity offerings likely if trials extend or fail.
  • Clinical trial execution risk in large randomized Phase 3 trial (PiNACLE-H2H).
  • LYL273 is early-stage with limited data; dose escalation could reveal toxicity.
  • Forward-looking statements carry significant uncertainty; no revenue from product candidates yet.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3255090

Track record

21 reports on LYEL

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +17.99% at T+60 after the Jun 8, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago S-3 Neutral 3/10 Entry $14.30 Now $14.65 +2.45% settles Nov 17
  2. Nov 12, 20264d ago Insider Cluster Bullish 6/10 Entry $14.30 to $14.65 Now $14.65 +2.45% ▲ +2.45% +4.36% vs SPY
  3. Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $16.86 to $15.64 Now $14.65 −13.11% ▼ −7.24% −6.88% vs SPY
  4. Nov 5, 202611d ago Insider Cluster Bullish 7/10 Entry $14.86 to $15.42 Now $14.65 −1.41% ▲ +3.77% +1.40% vs SPY
  5. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.00 to $14.86 Now $14.65 −2.33% ▼ −0.93% −1.25% vs SPY
  7. Nov 4, 202612d ago 8-K Bearish 5/10 Entry $15.43 to $15.00 Now $14.65 +5.06% ▲ +2.79% −1.62% vs SPY
  8. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.43 to $15.00 Now $14.65 −5.06% ▼ −2.79% +1.62% vs SPY
  9. Aug 25, 202611w ago Insider Cluster Neutral 4/10 Entry $14.80 to $14.61 Now $14.65 −1.01% ▼ −1.28% −1.94% vs SPY
  10. Jul 22, 202616w ago EFFECT Neutral 4/10 Entry $12.84 to $12.78 Now $14.65 +14.10% ▼ −0.47% +0.77% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 12, 2026